Practical Aspects of Vaccine Development The Practical Aspects
Coordonnateurs : Kolhe Parag, Ohtake Satoshi
Practical Aspects of Vaccine Development provides an academic and industry perspective on vaccine development and manufacturing. With the increasing complexity of vaccine products in development, there is a need for a comprehensive review of the current state of the industry and challenges being encountered. While formulation scientists working in biotherapeutic development may be familiar with proteins, vaccines present unique challenges. Vaccines include a wide range of components including proteins, polysaccharides, protein-polysaccharide conjugates, adjuvants, and more. The container closure system may also be unique, and the product may require freezing storage or lyophilization based on the stability of the vaccine components. Based on the route of delivery, novel technologies and devices may be required.
Covering formulation development, manufacture, and delivery considerations of vaccine production, this book is essential to formulation scientists, researchers in vaccine development throughout medical and life sciences, and advanced students.
Section 1: Formulation Development
1. Overview of vaccine antigens
Katherine Elizabeth Odneal
2. Overview of vaccine adjuvants
Mansoor M. Amiji, Rushit Lodaya, Sonia Gregory and Derek t. O’Hagan
3. Formulation considerations for Live attenuated vaccines
Lee Smith
4. Subunit based vaccines: Challenges in developing protein based vaccines
Charkes Middaugh and Salvador Fernando Ausar
5. Formulation development approaches and considerations for protein based vaccines
Malte Meppen and Daniela Stranges
6. DNA and RNA vaccines
Kanwal Gill, Leanne Minall and Aslin Rodriguez Nassif
7. Antigen-adjuvant formulation- Key considerations
Deep Bhattacharya, Aaron J. Latal, Vamsi Krishna Mudhivarthi and Chris Wiley II
8. Suspension Properties and Characterization of Aluminum-Adjuvanted Vaccines
Alex Langford
Section 2: Process Development
9. Effect of shipping stress on suspension vaccines
Jianxin Guo and Parag Kolhe
10. Developing control strategy for final dose concentration- Case study
Deep Bhattacharya and Parag Kolhe
11. Lyophilized vaccine development
Adora Padilla, Nicole Payton and Rushit Lodaya
Section 3: Delivery
12. Conventional and non-traditional delivery methods and routes of administration
Roberta Antonia Diotti, Giuseppe Andrea Sautto and Valeria Caputo
Formulation scientists, pharmacists, bioengineers, chemists or physicists in the pharmaceutical industry. Researchers and advanced students in pharmaceutical sciences.
Satoshi Ohtake, PhD, is an R&D professional with over 15 years of experience in the biotechnology industry, focusing on formulation and process development of various modalities ranging from small molecules to live attenuated vaccines. He has held positions of increasing responsibility at Nektar Therapeutics, Aridis Pharmaceuticals, and Pfizer. Dr. Ohtake is the inventor of over 10 patents and patent applications and author of over 40 peer-reviewed articles and book chapters. Additionally, he has delivered over 30 invited presentations. Dr. Ohtake received a B.S. from Caltech and a Ph.D. from the University of Wisconsin in Chemical Engineering. He is currently serving on the Journal of Pharmaceutical Sciences Editorial Advisory Board and the Caltech Alumni Association Board of Directors.
- Includes formulation considerations for various vaccine types, including proteins, polysaccharides, conjugates, and live vaccines
- Covers process development for solution, suspension, and lyophilized products
- Explores the future of vaccines, including multi-component vaccines and novel delivery mechanisms/devices
Date de parution : 09-2021
Ouvrage de 386 p.
19x23.4 cm
Thèmes de Practical Aspects of Vaccine Development :
Mots-clés :
Adjuvant; Adjuvanted vaccines; Adjuvants; Antigens; Attenuated; Chlamydia trachomatis; Clostridium difficile; Compatibility; Conjugates; Derma; Development; DoE; Dosage form; Epidermis; Excipients; Formulation composition; Formulation space; Formulation; Freeze-drying; Immune potentiators; Intramuscularand subcutaneous injection; Live viral vaccines; Live; Lyophilization; Microneedle; mRNA; Multicomponents vaccines; Nasal and oral delivery system; Norovirus; Particulateadjuvants; Pneumococcus; Potency; Preformulation; Protein; Protein-based vaccines; QbD; Quality by design; Recombinant proteins; Ricin; Scale-up; Stability; Stabilization; Subunit proteins; Toll-like-receptor agonists; Vaccine